NPJ VaccinesPub Date : 2025-07-16DOI: 10.1038/s41541-025-01213-x
Anabel Zabala-Peñafiel, Claudia Gonzalez-Lombana, Mohamad-Gabriel Alameh, Lais A Sacramento, Zhirong Mou, Anthony T Phan, Emily A Aunins, Ying K Tam, Jude E Uzonna, Drew Weissman, Christopher A Hunter, Phillip Scott
{"title":"IL-12 mRNA-LNP promotes dermal resident memory CD4<sup>+</sup> T cell development.","authors":"Anabel Zabala-Peñafiel, Claudia Gonzalez-Lombana, Mohamad-Gabriel Alameh, Lais A Sacramento, Zhirong Mou, Anthony T Phan, Emily A Aunins, Ying K Tam, Jude E Uzonna, Drew Weissman, Christopher A Hunter, Phillip Scott","doi":"10.1038/s41541-025-01213-x","DOIUrl":"10.1038/s41541-025-01213-x","url":null,"abstract":"<p><p>Dermal resident memory CD4<sup>+</sup> T cells (dTrm) provide protection against vector-borne infections. However, the factors that promote their development remain unclear. We tested if an mRNA vaccine, encoding a protective leishmanial antigen, induced dTrm cells. The mRNA vaccine induced robust systemic T-cell responses, but few Trm cells were found in the skin. Since IL-12 promotes Th1 responses, we tested whether IL-12 mRNA combined with the mRNA vaccine could enhance dTrm cell development. This combination significantly expanded Leishmania-specific Th1 cells expressing skin-homing molecules and memory T cell markers in the draining lymph node. Additionally, higher numbers of dTrm cells were maintained in the skin, and mice exhibited functional immunity indicated by a delayed hypersensitivity response and protection upon challenge with Leishmania. These findings highlight IL-12 as a key driver of CD4<sup>+</sup> dTrm development, enabling their global seeding across the skin, and underscore the potential of IL-12-enhanced mRNA vaccines to generate durable immunity against cutaneous leishmaniasis and other skin-targeted infections.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"154"},"PeriodicalIF":6.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2025-07-13DOI: 10.1038/s41541-025-01203-z
Guy de Bruyn, Haritha Adhikarla, Caroline K Brackett, Yichen Jia, Premkumar Lakshmanane, Sarah V Mudrak, Sheetal Sawant, Donghui Zhang, Roman M Chicz, Saranya Sridhar, Georgia D Tomaras, Kelly E Seaton
{"title":"Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines.","authors":"Guy de Bruyn, Haritha Adhikarla, Caroline K Brackett, Yichen Jia, Premkumar Lakshmanane, Sarah V Mudrak, Sheetal Sawant, Donghui Zhang, Roman M Chicz, Saranya Sridhar, Georgia D Tomaras, Kelly E Seaton","doi":"10.1038/s41541-025-01203-z","DOIUrl":"10.1038/s41541-025-01203-z","url":null,"abstract":"<p><p>We included measurement of pre-existing immunity to human endemic coronaviruses (HCoV) in a Phase I/II study of SARS-CoV-2 spike protein vaccine candidates. A Binding Antibody Multiplex Assay measured HCoV-specific IgG to the receptor binding domain or full-length spike of human coronaviruses HKU1, 229E, NL63, and OC43. We found no evidence for the impact of HCoV antibodies on neutralizing and binding antibody responses to the candidate SARS-CoV-2 vaccines.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"153"},"PeriodicalIF":6.9,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2025-07-12DOI: 10.1038/s41541-025-01207-9
Ahmed Mostafa, Chengjin Ye, Ramya S Barre, Vinay Shivanna, Reagan Meredith, Roy N Platt, Ruby A Escobedo, Mahmoud Bayoumi, Esteban M Castro, Nathaniel Jackson, Anastasija Cupic, Aitor Nogales, Timothy J C Anderson, Adolfo García-Sastre, Luis Martinez-Sobrido
{"title":"A live attenuated NS1-deficient vaccine candidate for cattle-origin influenza A (H5N1) clade 2.3.4.4.b viruses.","authors":"Ahmed Mostafa, Chengjin Ye, Ramya S Barre, Vinay Shivanna, Reagan Meredith, Roy N Platt, Ruby A Escobedo, Mahmoud Bayoumi, Esteban M Castro, Nathaniel Jackson, Anastasija Cupic, Aitor Nogales, Timothy J C Anderson, Adolfo García-Sastre, Luis Martinez-Sobrido","doi":"10.1038/s41541-025-01207-9","DOIUrl":"10.1038/s41541-025-01207-9","url":null,"abstract":"<p><p>Avian Influenza viruses (AIVs) present a public health risk, especially with seasonal vaccines offering limited protection. AIV H5N1 clade 2.3.4.4b has caused a multi-state outbreaks in the United States (US) poultry and cattle since March 2024, raising pandemic concerns. We developed a nonstructural protein 1 (NS1)-deficient mutant of a low pathogenic version of the cattle-origin human influenza A/Texas/37/2024 H5N1, namely LPhTXdNS1, and assessed its safety, immunogenicity, and protection efficacy. LPhTXdNS1 is attenuated in vitro, showing reduced replication efficiency in Vero cells and inability to control IFNβ promoter activation. The LPhTXdNS1-immunized C57BL/6 J mice exhibit significantly reduced viral replication and pathogenicity compared to those infected with the low pathogenic version expressing NS1, namely LPhTX. Notably, a single intranasal dose of LPhTXdNS1 elicited protective immune responses, providing robust protection against lethal wild-type H5N1 challenge. These results demonstrate that LPhTXdNS1 is safe and able to induce protective immune responses against H5N1.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"151"},"PeriodicalIF":6.9,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144619446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2025-07-12DOI: 10.1038/s41541-025-01205-x
Pengdi Chai, Yi Shi, Xiaoyan Li, Mengyao Yang, Xiafei Liu, Mei Liu, Junjie Yu, Xiaoxuan Yin, Dongwei Li, Ke Li, Xiangyu Kong, Qin Zhang, Hong Wang, Xiaoman Sun, Jinsong Li, Lili Li, Dandi Li, Lili Pang, Xuancheng Lu, Zhaojun Duan
{"title":"Improved mRNA-based RSV vaccine with PreF forming enveloped virus-like particles.","authors":"Pengdi Chai, Yi Shi, Xiaoyan Li, Mengyao Yang, Xiafei Liu, Mei Liu, Junjie Yu, Xiaoxuan Yin, Dongwei Li, Ke Li, Xiangyu Kong, Qin Zhang, Hong Wang, Xiaoman Sun, Jinsong Li, Lili Li, Dandi Li, Lili Pang, Xuancheng Lu, Zhaojun Duan","doi":"10.1038/s41541-025-01205-x","DOIUrl":"10.1038/s41541-025-01205-x","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) causes severe respiratory disease in infants and the elderly. However, natural infection fails to induce durable immune protection, and existing mRNA vaccines for older adults exhibit limited long-term efficacy. We developed an antigen engineering strategy inserting ESCRT/ALIX-binding region (EABR) into truncated RSV prefusion F (PreF) cytoplasmic tails to form enveloped virus-like particles (eVLPs). In murine models, PreF-EABR mRNA vaccines elicited higher, more persistent neutralizing antibodies than conventional PreF mRNA, correlating with enhanced germinal center B cell and memory B cell responses. A lower dose of PreF-EABR mRNA (1 μg) suppressed viral load and pathology comparable to higher-dose PreF mRNA (2.5 μg). Transcriptomic analysis showed PreF-EABR mRNA activated toll-like receptor and chemokine signaling pathways, enhancing antibody longevity via platelet-associated signatures. This study explores the development and possible mechanism of long-lasting RSV mRNA vaccines by eVLPs technology, which also suggest its potential application in other vaccines.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"152"},"PeriodicalIF":6.9,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144619447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2025-07-10DOI: 10.1038/s41541-025-01210-0
Yanjun Zhang, Yan Wu, Meng-Qian Zhang, Haiyue Rao, Zhaoyong Zhang, Xiangyue He, Yiwen Liang, Raoqing Guo, Yaochang Yuan, Jing Sun, Helen M E Duyvesteyn, Elizabeth E Fry, David I Stuart, Jingxian Zhao, XiaoYan Pan, Shu-Lin Liu, Jincun Zhao, Jiandong Huo
{"title":"Author Correction: An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.","authors":"Yanjun Zhang, Yan Wu, Meng-Qian Zhang, Haiyue Rao, Zhaoyong Zhang, Xiangyue He, Yiwen Liang, Raoqing Guo, Yaochang Yuan, Jing Sun, Helen M E Duyvesteyn, Elizabeth E Fry, David I Stuart, Jingxian Zhao, XiaoYan Pan, Shu-Lin Liu, Jincun Zhao, Jiandong Huo","doi":"10.1038/s41541-025-01210-0","DOIUrl":"10.1038/s41541-025-01210-0","url":null,"abstract":"","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"150"},"PeriodicalIF":6.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2025-07-10DOI: 10.1038/s41541-025-01209-7
Kirill Vasilev, Irene Hoxie, Eduard Puente-Massaguer, Joshua Yueh, Disha Bhavsar, Maya Singh, Corey P Mallett, Joseph Zimmermann, Florian Krammer
{"title":"Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvants.","authors":"Kirill Vasilev, Irene Hoxie, Eduard Puente-Massaguer, Joshua Yueh, Disha Bhavsar, Maya Singh, Corey P Mallett, Joseph Zimmermann, Florian Krammer","doi":"10.1038/s41541-025-01209-7","DOIUrl":"10.1038/s41541-025-01209-7","url":null,"abstract":"<p><p>Development of mucosal influenza virus vaccines which protect the site of viral entry is of high importance. Recombinant neuraminidase (NA) has emerged as an antigenically conserved intranasal vaccine candidate, capable of inducing broad cross-protection, but it requires effective mucosal adjuvants. Here, we analyze the immunogenicity and protective efficacy of a mucosal recombinant NA-based influenza virus vaccine adjuvanted with the outer membrane proteins from Neisseria meningitidis complexed with exogenous lipopolysaccharides (LPS) from Shigella flexneri or endogenous LPS from N. meningitidis. We observed increased follicular T-helper and germinal center B-cell population percentages in nasal-associated lymphoid tissue, enhanced IgA and IgG antibody responses, and accumulation of lung-resident memory T cells. The vaccine provided complete protection against homologous and partial protection against a heterologous influenza virus (clade 2.3.4.4b H5N1) challenge. These findings underscore the potential of bacterial membrane-derived adjuvants for developing robust mucosal influenza vaccines.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"149"},"PeriodicalIF":6.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2025-07-09DOI: 10.1038/s41541-025-01204-y
Jean Claude Balingit, Motoharu Abe, Ryosuke Suzuki, Dalouny Xayavong, Mya Myat Ngwe Tun, Yuki Takamatsu, Kengo Sonoda, Kouichi Morita
{"title":"Cross-genotype immunogenicity and antibody-dependent enhancement of KD-382 dengue vaccine in flavivirus-naïve adults.","authors":"Jean Claude Balingit, Motoharu Abe, Ryosuke Suzuki, Dalouny Xayavong, Mya Myat Ngwe Tun, Yuki Takamatsu, Kengo Sonoda, Kouichi Morita","doi":"10.1038/s41541-025-01204-y","DOIUrl":"10.1038/s41541-025-01204-y","url":null,"abstract":"<p><p>This exploratory study evaluated the neutralization breadth and potential antibody-dependent enhancement (ADE) risk following a single-dose of the KD-382 live-attenuated tetravalent dengue vaccine over 12 months in flavivirus-naïve healthy adults. Using single-round infectious particles representing 17 dengue virus genotypes, KD-382-induced antibodies demonstrated durable cross-genotype neutralizing activity, with minimal in vitro ADE risk. These findings highlight KD-382's potential for broad protection and underscore the importance of long-term monitoring in dengue-naïve populations.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"148"},"PeriodicalIF":6.9,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12241641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2025-07-07DOI: 10.1038/s41541-025-01208-8
Sandra Blome, Virginia Friedrichs, Alexander Schäfer, Martin Beer
{"title":"Benefit risk considerations for African swine fever virus live attenuated vaccines.","authors":"Sandra Blome, Virginia Friedrichs, Alexander Schäfer, Martin Beer","doi":"10.1038/s41541-025-01208-8","DOIUrl":"10.1038/s41541-025-01208-8","url":null,"abstract":"","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"147"},"PeriodicalIF":6.9,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12234875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2025-07-05DOI: 10.1038/s41541-025-01190-1
Marco Spinsanti, Elisabetta Monaci, Giacomo Romagnoli, Giada Buffi, Andrea Guido Oreste Manetti, Filippo Carboni, Giovanna Tuscano, Lucia Eleonora Fontana, Sara Tomei, Marta Zambelli, Rossella Cuffaro, Marianna Taccone, Chiara Sammicheli, Claudia Gianfaldoni, Francesca Angiolini, Maria Giuliani, Sara Marchi, Silvia Senesi, Christian Matano, Ivan Pisoni, Nathalie Norais, Maria Rosaria Romano, Silvia Rossi Paccani, Silvana Savino, Alessandro Muzzi, Federico Fontani, Davide Serruto, Michela Brazzoli, Giulia Giordano, Monica Fabbrini, Ugo D'Oro, Oretta Finco, Immaculada Margarit, Isabel Delany, Erika Bartolini
{"title":"A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice.","authors":"Marco Spinsanti, Elisabetta Monaci, Giacomo Romagnoli, Giada Buffi, Andrea Guido Oreste Manetti, Filippo Carboni, Giovanna Tuscano, Lucia Eleonora Fontana, Sara Tomei, Marta Zambelli, Rossella Cuffaro, Marianna Taccone, Chiara Sammicheli, Claudia Gianfaldoni, Francesca Angiolini, Maria Giuliani, Sara Marchi, Silvia Senesi, Christian Matano, Ivan Pisoni, Nathalie Norais, Maria Rosaria Romano, Silvia Rossi Paccani, Silvana Savino, Alessandro Muzzi, Federico Fontani, Davide Serruto, Michela Brazzoli, Giulia Giordano, Monica Fabbrini, Ugo D'Oro, Oretta Finco, Immaculada Margarit, Isabel Delany, Erika Bartolini","doi":"10.1038/s41541-025-01190-1","DOIUrl":"10.1038/s41541-025-01190-1","url":null,"abstract":"<p><p>Gonorrhea, caused by Neisseria gonorrhoeae (GC) represents a significant public health threat that may be mitigated by an effective vaccine. Vaccines containing N. meningitidis outer membrane vesicles (OMVs), such as 4CMenB, demonstrated moderate effectiveness in preventing GC infections. Here, we developed NgG, an investigational GC vaccine based on Generalized Modules for Membrane Antigens (GMMA). NgG includes genetically detoxified OMVs from the FA1090 strain, engineered to reduce endotoxin activity and limit immune interference. NgG induced a robust immune response in mice and outperformed the comparator vaccine 4CMenB in several serological and functional tests. Immunization with GMMA from a FA1090 mutant, where major oligosaccharide epitopes are incomplete or absent, revealed that NgG lipooligosaccharide plays a major role in the breadth of functional responses, with protein component also contributing in some GC strains. These results suggest that NgG has the potential to block GC infection through various mechanisms, supporting further vaccine development.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"146"},"PeriodicalIF":6.9,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2025-07-04DOI: 10.1038/s41541-025-01160-7
Rineke de Jong, Sandra Vreman, Katrin E Wiese, Nora M Gerhards, Kevin R Bewley, Yper Hall, Francisco Javier Salguero, Miles Carroll, Rik L de Swart, Jose L Gonzales, Nadia Oreshkova
{"title":"Hamsters immunized with formalin-inactivated SARS-CoV-2 develop accelerated lung histopathological lesions and Th2-biased response following infection.","authors":"Rineke de Jong, Sandra Vreman, Katrin E Wiese, Nora M Gerhards, Kevin R Bewley, Yper Hall, Francisco Javier Salguero, Miles Carroll, Rik L de Swart, Jose L Gonzales, Nadia Oreshkova","doi":"10.1038/s41541-025-01160-7","DOIUrl":"10.1038/s41541-025-01160-7","url":null,"abstract":"<p><p>One of the concerns regarding vaccine safety during the COVID-19 pandemic was the potential manifestation of vaccine-associated enhancement of disease (VAED) upon SARS-CoV-2 infection. To investigate the suitability of the Syrian hamster model to test for VAED, we immunized animals with an experimental formaldehyde-inactivated, alum-adjuvanted SARS-CoV-2 vaccine preparation. In two independent experiments, challenge infection did not result in an enhancement of the clinical disease in vaccinated animals compared with mock-vaccinated animals. However, at early timepoints (2-5 days) post-challenge, lung histopathology progressed faster and was more prominent in vaccinated hamsters and lung tissue showed elevated mRNA levels of IL-4 and IL-13. At later time points, cytokine responses and lung pathology were comparable between vaccinated and mock-vaccinated hamsters, underscoring the transient nature of the pathological aggravation. With this work we show that the Syrian hamster model can be used to assess possible vaccine safety considerations in a preclinical setting.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"145"},"PeriodicalIF":6.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}